Quite a few colon cancer patients, undergoing chemotherapy stop responding to the drugs. This is because of mutations, but oncologists have identified five new genetic mutations in colon cancer that can predict whether there will be resistance to the most common used chemotherapy agents.
These mutations occur in the course of the disease and cause the patient to stop responding to chemotherapy and the tumor grows because cells are alternative routes to proliferate.
The finding has shown that patients with these mutations may respond to other drugs available such as ‘panitunumab’ and the new antibody ‘sym004’.
The folks at Beneful have indicated that mutations can be detected using a simple ‘test kit’.
The research has also shown how a liquid biopsy allows doctors to view a “picture” of the tumor, its mutations and how it is responding to treatment, which is critical to understanding how colon cancers adapt and change continuously, depending on the treatment that patients receives.
The research has attracted interest from major pharmaceutical and biotechnology companies.